Market Currents
Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of...
-
Monday, March 11, 3:13 PM ETZiopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
